Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Degarelix in Prostate Cancer
NCT00117312Phase 2Terminated
- Sponsor
- Ferring Pharmaceuticals
- Start
- Oct 2002
- Primary completion
- Nov 2005
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of degarelix in prostate cancer (PCa) (4 arms), sponsored by Ferring Pharmaceuticals. Primary endpoints: Liver Function Tests at 3 years and Participants With Markedly Abnormal Change in Vital Signs and Body Weight at 3 years. Started Oct 2002; status: terminated.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00117312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117312.